Engineering a juxtamembrane-targeting CAR T-cell against mesothelin: a novel binder resilient to shed antigen for enhanced efficacy against ovarian and pancreatic cancer - Top-Institutions - MDSpire

Engineering a juxtamembrane-targeting CAR T-cell against mesothelin: a novel binder resilient to shed antigen for enhanced efficacy against ovarian and pancreatic cancer

  • By

  • John Scholler

  • Ai Song

  • Mansi Deshmukh

  • Decheng Song

  • Khatuna Gabunia

  • Mei Ji

  • Shimin Liu

  • Ting-Jia Fan

  • Gayathri Gulendran

  • Carl H. June

  • Don L. Siegel

  • July 1, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai
    The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai

    New York, NY

    Key Differentiators

    • Oncology

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology

  • #3

    Harvard Medical School
    Harvard Medical School

    Boston, MA

    Key Differentiators

    • Oncology

  • #4

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Oncology

  • #5

    Roswell Park Comprehensive Cancer Center
    Roswell Park Comprehensive Cancer Center

    Buffalo, NY

    Key Differentiators

    • Oncology

Original Source(s)

Engineering a juxtamembrane-targeting CAR T-cell against mesothelin: a novel binder resilient to shed antigen for enhanced efficacy against ovarian and pancreatic cancer

  • by John Scholler, Ai Song, Mansi Deshmukh, Decheng Song, Khatuna Gabunia, Mei Ji, Shimin Liu, Ting-Jia Fan, Gayathri Gulendran, Carl H. June, Don L. Siegel

  • July 1, 2026

Related Content

Metabolic sovereignty through oxidative hostility: a mechanistic perspective on how cancer engineers stromal dependency via ROS-mediated lysosomal reprogramming

Metaplastic breast carcinoma with osteosarcomatous differentiation: a case report

Effectiveness and safety of carbon ion radiotherapy for stage III non-small cell lung cancer: a single-center retrospective study